title: Evaluation of fast disintegrating lansoprazole tablet in human subjects.
abstract: Fast disintegrating lansoprazole tablet (LFDT) has been developed as a multiple unit formulation and evaluated using human subjects as compared to the conventional lansoprazole (LPZ) capsule containing enteric coated granules. Twelve healthy male volunteers, who were confirmed as extensive metabolizers (EMs) based on the plasma levels of LPZ sulphone metabolite, were enrolled into the study and genotype of CYP2C19 was confirmed. They kept 30 mg LFDT in their mouths for 2 min and the saliva was recovered without swallow. Eight subjects did not show LPZ in their serum after intake. Although LPZ was detected in 4 subjects' serum, their concentrations were less than 5 ng/mL. LPZ was thought to be not absorbed from the oral cavity. LFDT was orally administered to 12 healthy male EMs at two doses, 15 mg and 30 mg, and serum LPZ concentrations were measured. The mean C(max) and AUC(0-24) were 474.1+/-254.0 ng/mL and 1105.3+/-1101.4 ng.h/mL (15 mg) and 992.8+/-384.3 ng/mL and 2216.5+/-1270.1 ng.h/mL (30 mg). By comparing to that obtained after oral administration of the same doses of LPZ capsule, serum LPZ concentration vs. time curve was almost the same level, i.e., C(max) and AUC(0-24) did not have significant differences. From these results, LFDT has been shown to be equivalent to LPZ capsule and will show the same acid suppressing effects in the clinical situation.
authors.affiliation: Department of Pharmacokinetics, Kyoto Pharmaceutical University, Japan. Iwasaki_Kouji@takeda.co.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Iwasaki
authors.forename: Yukako
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Nobuhito
authors.initials: N
authors.lastname: Shibata
authors.forename: Kanji
authors.initials: K
authors.lastname: Takada
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sakurai
authors.forename: Naoshi
authors.initials: N
authors.lastname: Takagi
authors.forename: Shin
authors.initials: S
authors.lastname: Irie
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakamura
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D064747:Lansoprazole; D009061:Mouth Mucosa / Q000378:metabolism; D009853:Omeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D012463:Saliva / Q000378:metabolism; D013607:Tablets
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D013607:Tablets; D064747:Lansoprazole; D009853:Omeprazole